Catalog No.
EHB87401
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Glu622
Predicted molecular weight
71.00 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P00734
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
F2, Coagulation factor II, Prothrombin, PIVKA-II, DCP, Vitamin K Absence or Antagonist-II, Des-γ-carboxy-prothrombin, PIVKA II
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
CTSE inhibits anti-tumor T cell response by promoting des-γ-carboxy prothrombin releasing in hepatocellular carcinoma., PMID:40467555
[Study on the value of abnormal prothrombin in the diagnosis of HBV-related hepatocellular carcinoma]., PMID:40419369
[Research progress and clinical application in the early diagnosis and treatment technology of hepatocellular carcinoma]., PMID:40419364
Predictability of clinical outcomes after external beam radiotherapy for hepatocellular carcinoma according to tumor marker dynamics., PMID:40392828
Development of a chitosanase 3-like protein 1 assay kit and study of its application in patients with hepatocellular carcinoma., PMID:40355912
Performance of the GALAD Model in an Asian Cohort Undergoing Hepatocellular Carcinoma Surveillance: A Prospective Cohort Study., PMID:40346978
Elevated Serum Protein Induced by Vitamin K Absence or Antagonist II Levels in Patients with Hepatic Hemangiomas., PMID:40332214
The GALAD score performs better than AFP in hepatocellular carcinoma screening: a single-centre, case-control study in Malaysia., PMID:40303589
Combining AFP, PIVKA-II, and GP73 has diagnostic utility for hepatitis B-associated hepatocellular carcinoma and is consistent with liver pathology results., PMID:40295542
Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial., PMID:40263401
Establishment and Validation of Diagnostic Model of Microvascular Invasion in Solitary Hepatocellular Carcinoma., PMID:40254744
Evaluation of serum ESPL1 as a biomarker for early diagnosis of HBV-related hepatocellular carcinoma., PMID:40248196
Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models., PMID:40247208
Relationship between MTHFR 677C > T polymorphism and serum PIVKA-II levels in hepatocellular carcinoma., PMID:40243201
A Large-Scale Retrospective Study of Serum Des-Gamma-Carboxy Prothrombin as a Diagnostic Marker of HCC: Effect of Liver Function on Specificity., PMID:40230049
One Case of Abnormal Elevation of PIVKA-II., PMID:40209781
A Case of Advanced Non-Small Cell Lung Cancer With Hepatocellular Carcinoma-Like Features Responding to a Combination of Durvalumab, Tremelimumab, Carboplatin, and Nab-Paclitaxel., PMID:40161114
Tumor biology characteristics score based on alpha-fetoprotein and protein induced by vitamin K absence or antagonist II as a predictor for recurrence and survival after curative resection for hepatocellular carcinoma: a multicenter cohort study., PMID:40157713
Cost-Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers., PMID:40135830
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study., PMID:40117651
Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection., PMID:40045063
CA19-9, CEA and PIVKA-Ⅱ as a novel panel of serum markers for diagnosis of pancreatic cancer., PMID:40024361
Cachexia is an independent predictor of mortality in patients with hepatocellular carcinoma on systemic targeted therapy., PMID:39993564
Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD., PMID:39980834
Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma., PMID:39962429
Exosome biosensors for detection of liver cancer., PMID:39961411
One Milligram Versus Two Milligram Intramuscular Vitamin K to Prevent Late-Onset Hemorrhagic Disease in Young Infants: A Randomized Controlled Trial., PMID:39912270
PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma., PMID:39905360
Cluster analysis of hepatocellular carcinoma prognosis using preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin levels: a multi-institutional study., PMID:39884550
Vitamin K1 Administration Increases the Level of Circulating Carboxylated Osteocalcin in Critically Ill Patients., PMID:39861478
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma., PMID:39857948
Tumor Markers in Pleural Fluid: A Comprehensive Study on Diagnostic Accuracy., PMID:39857088
A new platform of electrowetting-on-dielectric digital microfluidics for rapid detection of early-stage Hepatocellular Carcinoma(HCC) specific biomarker., PMID:39788685
Membranous Overexpression of Fibronectin Predicts Microvascular Invasion and Poor Survival Outcomes in Patients with Hepatocellular Carcinoma., PMID:39778882
Clinical Value of Abnormal Prothrombin and Carbohydrate Antigen 125 in the Diagnosis of Patients With Gallbladder Cancer., PMID:39754532
Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization., PMID:39749461
Prognostic factor and risk stratification in hepatocellular carcinoma: insights from Cox regression and Kaplan-Meier analysis in a male-dominated cohort., PMID:39749372
Prolonged prothrombin time in hyperemesis gravidarum as an indicator of vitamin K deficiency., PMID:39746218
Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy., PMID:39726604
Comparative Validation of Prediction Models for HCC Outcomes in Living Donor Liver Transplantation: Superiority of Tumor Markers to Imaging Study., PMID:39723645
GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease., PMID:39688172
Comprehensive study of various vitamin concentrations in the human postmortem blood with an autopsy case report of beriberi., PMID:39671809
Vessels encapsulating tumor clusters contribute to the intratumor heterogeneity of HCC on Gd-EOB-DTPA-enhanced MRI., PMID:39670871
Enhancing the prognostic accuracy of the RETREAT score with AFP-L3 and DCP tumor markers., PMID:39661334
Prognostic Role of Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Post Stereotactic Body Radiation in Advanced Hepatocellular Carcinoma., PMID:39654812
PIVKA-II but not dp-ucMGP is associated with aortic calcification in chronic kidney disease., PMID:39604863
Prospective appraisal of clinical diagnostic algorithms for hepatocellular carcinoma surveillance in Chinese patients with chronic hepatitis B infection., PMID:39578653
Identification of serum tsRNA-Thr-5-0015 and combined with AFP and PIVKA-II as novel biomarkers for hepatocellular carcinoma., PMID:39572775
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA., PMID:39569574
For research use only. Not for human or drug use.
